Nasdaq nmra.
NASDAQ: NMRA. $11.69-0.16 (-1.35%) Updated Nov 21, 2023. Open eToro Account. FAQ. How much does it cost to buy one Neumora Therapeutics share? As of . Nov 21, 2023, it costs $11.69 to buy one share of Neumora Therapeutics stock.Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs.
Explore Neumora Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 46 news, and 3 literature, Disease Domain ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...
Indivior Stock (NASDAQ: INDV) stock price, news, charts, stock research, profile.Neumora Therapeutics press release (NASDAQ:NMRA): Q3 GAAP EPS of -$1.14 misses by $0.74. $519.5 million in cash, cash equivalents and marketable securities expected to support operations into 2026.Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...
Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...Sep 28, 2023 · VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...
Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.2 hari yang lalu ... Read William Blair Brokers Cut Earnings Estimates for Neumora Therapeutics, Inc. (NASDAQ:NMRA) at Techdows.Neumora (NASDAQ: NMRA) develops precision medicines to restore brain health. It focuses on discovering, developing, and commercializing targeted therapies for people living with brain diseases. The company was founded in …Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...
On Invalid Date, . Neumora Therapeutics (NASDAQ: NMRA) reported Q3 2023 earnings per share (EPS) of -$1.14, up 7.55% year over year. Total Neumora Therapeutics earnings for the quarter were -$53.03 million.In the same quarter last year, Neumora Therapeutics's earnings per share (EPS) was -$1.06.
About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora.
Neumora Therapeutics Inc. (NASDAQ:NMRA)’s traded shares stood at 0.14 million during the last session. At the close of trading, the stock’s price was $11.91, to imply an increase of 1.88% or $0.22 in intraday trading. The NMRA share’s 52-week high remains $17.74, putting it -48.95% down since ...Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ... On Invalid Date, . Neumora Therapeutics (NASDAQ: NMRA) reported Q3 2023 earnings per share (EPS) of -$1.14, up 7.55% year over year. Total Neumora Therapeutics earnings for the quarter were -$53.03 million.In the same quarter last year, Neumora Therapeutics's earnings per share (EPS) was -$1.06.About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora.Oct 10, 2023 · WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ... A. The latest price target for Tilray Brands ( NASDAQ: TLRY) was reported by Roth MKM on Friday, September 1, 2023. The analyst firm set a price target for 2.50 expecting TLRY to rise to within 12 ...Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …
Neumora Therapeutics, Inc. (NASDAQ:NMRA) shares fell 8% to $11.02. Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) fell 7.4% to $9.97. BeiGene, Ltd. (NASDAQ:BGNE) fell 7.2% to $193.86. B of A ...Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the ...Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 12.33 +0.08 (0.65%) Dec 1, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 78.43%. The lowest target is $18 …
According to the issued ratings of 6 analysts in the last year, the consensus rating for Neumora Therapeutics stock is Buy based on the current 6 buy ratings for NMRA. The average twelve-month price prediction for Neumora Therapeutics is $22.67 with a high price target of $26.00 and a low price target of $18.00.Ventyx Biosciences, Inc. (NASDAQ:VTYX) fell 22.1% to $23.38 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.
The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Wednesday, November 8, 2023. The analyst firm set a price target ...Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.What happenedShares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...
NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $11.91 +0.22 (+1.88%) (As of 11/22/2023 ET) Compare Today's Range $11.76 $12.14 50-Day Range $9.64 $16.25 52-Week Range $9.35 $17.74 Volume 137,979 shs Average Volume 342,316 shs Market Capitalization $1.82 billion P/E Ratio N/A Dividend Yield N/A Price Target $22.67
Canopy Growth Corporation Common Shares. $1.165 -0.175 -13.06%. NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting ...
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for ...Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity ...Visualize o gráfico de Neumora Therapeutics, Inc. ao vivo para acompanhar o movimento do preço de suas ações. Encontre previsões de mercado, NMRA finanças e notícias do mercado.View Your Watchlist. Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and …Neumora (NASDAQ: NMRA) develops precision medicines to restore brain health. It focuses on discovering, developing, and commercializing targeted therapies for people living with brain diseases. The company was founded in …Sep 15, 2023 · The Watertown, MA-based Neumora Therapeutics ( NASDAQ: NMRA ), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its ... NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 12.33 +0.08 (0.65%) Dec 1, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 78.43%. The lowest target is $18 …Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …
View real-time NMRA stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...The latest price target for Structure Therapeutics ( NASDAQ: GPCR) was reported by JMP Securities on Monday, November 20, 2023. The analyst firm set a price target for 91.00 expecting GPCR to rise ...Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ... Aug 28, 2023 · AzmanJaka. A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration ... Instagram:https://instagram. can you take out equity from your home without refinancingabbv cls 484cryptocurrency brokers in usaautomated stock trading platform WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... learn investment managementfdrrx Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI … trusted companion dog training Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.NMRA | Complete Neumora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.